Stereotactic body radiotherapy (SBRT) versus high dose rate (HDR) brachytherapy (BT) boost for high-risk (HR) prostate cancer.

被引：1
|
作者：
Gonzalez-Motta, Alejandro
Roach, Mack
机构：
[1] Inst Nacl Canc, Bogota, Colombia
[2] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genitourinary (GU) Toxicity in Patients with Intermediate and High-Risk Prostate Cancer Managed with Hypofractionated External Radiation and High Dose Rate (HDR) Brachytherapy Boost
    Goel, A.
    Liu, C. M.
    Kaur, P.
    Wong, M. L.
    Scala, L. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E113 - E113
  • [32] Survial Endpoints Comparing HDR BT Boost To EBRT Boost For High/Intermediate-Risk Prostate Cancer.
    Rodriguez Villalba, S.
    Richart Sancho, J.
    Perez-Calatayud, J.
    Lago Martin, J. D.
    Santos Ortega, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1253 - S1254
  • [33] Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
    Foerster, Robert
    Zwahlen, Daniel Rudolf
    Buchali, Andre
    Tang, Hongjian
    Schroeder, Christina
    Windisch, Paul
    Vu, Erwin
    Akbaba, Sati
    Bostel, Tilman
    Sprave, Tanja
    Zamboglou, Constantinos
    Zilli, Thomas
    Stelmes, Jean-Jacques
    Telkhade, Tejshri
    Murthy, Vedang
    [J]. CANCERS, 2021, 13 (04) : 1 - 17
  • [34] Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes
    Loblaw, Andrew
    Musunuru, Bindu
    Cheung, Patrick
    Vesprini, Danny
    Liu, Stanley K.
    Chu, William
    Chung, Hans T.
    Morton, Gerard
    Deabreu, Andrea
    Davidson, Melanie
    Ravi, Ananth
    Helou, Joelle
    Ho, Ling
    Zhang, Liying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] SBRT Boost for Intermediate and High-Risk Prostate Cancer. Results of a single Chilean institution
    Sanchez, M. F.
    Bakal, F.
    Troncoso, A.
    Bettoli, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1175 - S1176
  • [36] Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach
    Mikropoulos, C.
    Otter, S.
    Perna, C.
    Khaksar, S.
    Franklin, A.
    Laing, R.
    Uribe, J.
    Lewis, S. U.
    Langley, S.
    [J]. CLINICAL ONCOLOGY, 2020, 32 (07) : E162 - E162
  • [37] Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
    Lischalk, Jonathan W.
    Malik, Ryan M.
    Collins, Sean P.
    Collins, Brian T.
    Matus, Ismael A.
    Anderson, Eric D.
    [J]. RADIATION ONCOLOGY, 2016, 11
  • [38] Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
    Jonathan W. Lischalk
    Ryan M. Malik
    Sean P. Collins
    Brian T. Collins
    Ismael A. Matus
    Eric D. Anderson
    [J]. Radiation Oncology, 11
  • [39] Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E342 - E347
  • [40] PROSTATE SBRT BOOST RADIOTHERAPY (PBS TRIAL): A RANDOMIZED PHASE II TRIAL OF SBRT VERSUS CONVENTIONALLY-FRACTIONATED RADIOTHERAPY BOOST FOLLOWING PELVIC RADIOTHERAPY IN HIGH-RISK PROSTATE CANCER
    Mesci, Aruz
    Isfahanian, Naghmeh
    Douvi, Georgia
    Gouran-Savadkoohi, Mohammad
    Dayes, Ian
    Lukka, Himanshu
    Quan, Kimmen
    Schnarr, Kara
    Goldberg, Mira
    Hallock, Abhirami
    Chow, Tom
    Diamond, Kevin
    Jakubovic, Raphael
    Thabane, Lahane
    Tsakiridis, Theodoros
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S64 - S64
12345